Evidence map›Paper›PMID 42241367›Full record

ReviewActa haematologica2026

Shared Care Offers an Effective Framework for Managing Tagraxofusp Treatment in Blastic Plasmacytoid Dendritic Cell Neoplasm.

Alexander Ambinder, Thomas W LeBlanc, M Yair Levy, Ami B Patel, James McCloskey, Erin Duffield, John Katsetos, Gabriel Mannis

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Acta haematologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Alexander AmbinderThe Johns Hopkins Hospital, Baltimore, Maryland, USA, aambind1@jhmi.edu.
Thomas W LeBlancDuke University School of Medicine, Durham, North Carolina, USA.
M Yair LevyBaylor Scott and White Health, Dallas, Texas, USA.
Ami B PatelHuntsman Cancer Institute, Salt Lake City, Utah, USA.
James McCloskeyHackensack University Medical Center, Hackensack, New Jersey, USA.
Erin DuffieldHuntsman Cancer Institute, Salt Lake City, Utah, USA.
John KatsetosMenarini Group, New York, New York, USA.
Gabriel MannisDepartment of Medicine, Division of Hematology, Stanford University, Stanford, California, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTagraxofusp, a first-in-class CD123-targeted therapy, is the only approved treatment for blastic plasmacytoid dendritic cell neoplasm (BPDCN). Shared care models enable coordination and care delivery between specialized cancer treatment centers and local institutions, allowing eligible patients to receive tagraxofusp. SUMMARY: This review provides guidance on best practices for effective shared care implementation for tagraxofusp in patients with BPDCN, including appropriate patient selection, adequate local institutional readiness, proactive collaboration and communication between institutions, integrated comanagement between institutions, and requisite staff, patient, and caregiver education. KEY MESSAGES: Shared care is particularly suitable for tagraxofusp treatment, as adverse events can be grade 3 or greater, but typically only occur in cycle 1, if they are to occur at all. Based on clinical experience, this article discusses the application of a shared care model for tagraxofusp treatment in BPDCN.

Indexed as

Blastic plasmacytoid dendritic cell neoplasmCD123Collaborative careHealthcare deliveryShared careSupportive careTagraxofusp

Identifiers

PMID42241367
PMCPMC13349363

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.